Cullinan Therapeutics Inc
CGEM
查看详细走势图
10.370USD
+0.110+1.07%
收盘 12/26, 16:00（美东）报价延迟15分钟
612.62M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+1.07%
5天
+7.13%
1月
-11.67%
6月
+33.63%
今年开始到现在
-14.86%
1年
-13.73%
查看详细走势图
TradingKey Cullinan Therapeutics Inc股票评分
单位: USD 更新时间: 2025-12-26操作建议
Cullinan Therapeutics Inc当前公司基本面数据相对谨慎，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名66/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价31.10。中期看，股价处于上升通道。近一个月，市场表现较差，但技术面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Cullinan Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
11
位分析师
买入
评级
31.100
目标均价
+150.00%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Cullinan Therapeutics Inc亮点
亮点风险
Cullinan Therapeutics, Inc. is a biopharmaceutical company. It has built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in autoimmune diseases and cancer. Its portfolio includes a range of modalities. Its pipeline includes CLN-978, CLN-619, Zipalertinib (CLN-081/TAS6417), CLN-049, and CLN-617. CLN-978 is a CD19xCD3 T cell engager being developed for autoimmune diseases. CLN-619 is a monoclonal antibody that stabilizes expression of MICA/B on the tumor cell surface to promote tumor cell lysis mediated by cytotoxic innate and adaptive immune cells. Zipalertinib (CLN-081/TAS6417) is an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor. CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-617 is a fusion protein combining two potent antitumor cytokines, interleukin-2 and interleukin-12 with tumor retention domains for the treatment of solid tumors.
估值合理
公司最新PE估值-2.81，处于3年历史合理位
机构加仓
最新机构持股64.92M股，环比增加4.72%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓，最新持仓市值523.00
Cullinan Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Cullinan Therapeutics Inc简介
Cullinan Therapeutics, Inc. is a biopharmaceutical company. It has built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in autoimmune diseases and cancer. Its portfolio includes a range of modalities. Its pipeline includes CLN-978, CLN-619, Zipalertinib (CLN-081/TAS6417), CLN-049, and CLN-617. CLN-978 is a CD19xCD3 T cell engager being developed for autoimmune diseases. CLN-619 is a monoclonal antibody that stabilizes expression of MICA/B on the tumor cell surface to promote tumor cell lysis mediated by cytotoxic innate and adaptive immune cells. Zipalertinib (CLN-081/TAS6417) is an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor. CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-617 is a fusion protein combining two potent antitumor cytokines, interleukin-2 and interleukin-12 with tumor retention domains for the treatment of solid tumors.
公司代码CGEM
公司Cullinan Therapeutics Inc
CEOAhmed (Nadim)
网址https://cullinantherapeutics.com/
常见问题
Cullinan Therapeutics Inc(CGEM)的当前股价是多少？
Cullinan Therapeutics Inc(CGEM)的当前股价是 10.370。
Cullinan Therapeutics Inc的股票代码是什么？
Cullinan Therapeutics Inc的股票代码是CGEM。
Cullinan Therapeutics Inc股票的52周最高点是多少？
Cullinan Therapeutics Inc股票的52周最高点是13.330。
Cullinan Therapeutics Inc股票的52周最低点是多少？
Cullinan Therapeutics Inc股票的52周最低点是5.680。
Cullinan Therapeutics Inc的市值是多少？
Cullinan Therapeutics Inc的市值是612.62M。
Cullinan Therapeutics Inc的净利润是多少？
Cullinan Therapeutics Inc的净利润为-167.38M。
现在Cullinan Therapeutics Inc(CGEM)的股票是买入、持有还是卖出？
根据分析师评级，Cullinan Therapeutics Inc(CGEM)的总体评级为买入，目标价格为31.100。
Cullinan Therapeutics Inc(CGEM)股票的每股收益（EPS TTM）是多少
Cullinan Therapeutics Inc(CGEM)股票的每股收益（EPS TTM）是-3.684。
相关品种
